首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3064篇
  免费   186篇
  国内免费   99篇
耳鼻咽喉   16篇
儿科学   21篇
妇产科学   14篇
基础医学   128篇
口腔科学   50篇
临床医学   212篇
内科学   139篇
皮肤病学   18篇
神经病学   36篇
特种医学   107篇
外科学   88篇
综合类   518篇
预防医学   256篇
眼科学   12篇
药学   885篇
  3篇
中国医学   691篇
肿瘤学   155篇
  2024年   25篇
  2023年   65篇
  2022年   122篇
  2021年   155篇
  2020年   140篇
  2019年   108篇
  2018年   110篇
  2017年   94篇
  2016年   108篇
  2015年   83篇
  2014年   196篇
  2013年   180篇
  2012年   182篇
  2011年   218篇
  2010年   177篇
  2009年   157篇
  2008年   156篇
  2007年   146篇
  2006年   86篇
  2005年   135篇
  2004年   96篇
  2003年   85篇
  2002年   40篇
  2001年   61篇
  2000年   45篇
  1999年   50篇
  1998年   57篇
  1997年   32篇
  1996年   38篇
  1995年   34篇
  1994年   31篇
  1993年   25篇
  1992年   13篇
  1991年   5篇
  1990年   11篇
  1989年   9篇
  1988年   9篇
  1987年   3篇
  1986年   6篇
  1985年   9篇
  1984年   7篇
  1983年   4篇
  1982年   9篇
  1981年   7篇
  1980年   6篇
  1979年   3篇
  1978年   2篇
  1977年   2篇
  1974年   2篇
  1972年   2篇
排序方式: 共有3349条查询结果,搜索用时 15 毫秒
111.
目的:研究金欣口服液含药血清对呼吸道合胞病毒(RSV)黏附、膜融合的影响。方法:在病毒和细胞接触期间采用转换温度方法观察金欣口服液含药血清对RSV黏附、侵入的影响。结果:温度转换前(黏附阶段)加入金欣口服液含药血清,实验组和对照组OD值无差异;温度转换后(侵入阶段)加入金欣口服液含药血清组OD值明显升高,与对照组比有显著性差异。结论:金欣口服液含药血清的抗病毒作用在呼吸道合胞病毒黏附后的膜融合及侵入阶段。  相似文献   
112.
Topical 5% alpha lipoic acid (ALA) has shown efficacy in treatment of photo-damaged skin. The aim of this work was to evaluate the potential of poloxamer (P407) gel as a vehicle for the novel lipid base particulate system (cubosome dispersions) of ALA. Cubosome dispersions were formulated by two different approaches, emulsification of glyceryl monoolein (GMO) and poloxamer (P407) in water followed by ultrasonication, and the dilution method using a hydrotrope. Three different concentrations of GMO were used to formulate the cubosome dispersions using the first method, 5% (D1), 10% (D2) and 15% w/w (D3). In the second technique an isotropic liquid was produced by combining GMO with ethanol, and this isotropic liquid was then diluted with a P407 solution (D4). The dispersions were characterized by zeta potential, light scattering techniques, optical and transmission electron microscopy, encapsulation efficiency and in vitro drug release. Results showed that D4 was not a uniform dispersion and that D1, D2 and D3 were uniform dispersions, in which by increasing the GMO content in the dispersion, the size of the cubosomes decreased, zeta potential became more negative, encapsulation efficiency increased up to 86.48% and the drug release rate was slower. P407 gels were prepared using the cold method. Two concentrations of P407 gel were fabricated, 20 and 30% w/w. P407 gels were loaded with either ALA or dispersions containing ALA cubosomes. P407 gels were characterized by critical gelation temperature, rheological measurements and in vitro drug release studies. Results suggested that by increasing P407 concentration, the gelation temperature decreases and viscosity increases. Drug release in both cases was found to follow the Higuchi square root model. Gel loaded with ALA cubosomes provided a significantly lower release rate than the gel loaded with the un-encapsulated ALA. A double blinded placebo controlled clinical study was conducted, aiming to evaluate the efficacy as an anti-wrinkle agent and volunteer’s satisfaction upon application of topical 30% P407 gel loaded with ALA cubosomes. Results indicated reduction in facial lines, almost complete resolution of fine lines in the periorbital region and upper lip area and overall improvement in skin color and texture in most volunteers. There were no instances of irritation, peeling or other apparent adverse side effects.  相似文献   
113.
目的考察益精灵口服液长期给药对大鼠的影响,为临床安全用药提供科学依据。方法将大鼠随机分为对照组及益精灵口服液低[0.5 mL/(kg·d)]、中[2.5 mL/(kg·d)]、高[5mL/(k·d)]剂量组,分别相当于临床患者每日用量的1,5,10倍,30 d后每组随机处死雌雄大鼠各5只,取尾静脉血进行血常规检查,包括测定血红蛋白(Hb)、白细胞计数(WBC)、红细胞计数(RBC);血液生化指标检查,包括天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBil);取大鼠心、肝、肾、肺作组织病理学检查。结果连续给药30 d后,各剂量组动物的体重、血液生化指标、血常规未发生变化。各剂量组动物的心、肝、肾、肺均未见有明显的病理改变。结论益精灵口服液临床用药较安全。  相似文献   
114.
目的 建立测定小儿解表止咳口服液中盐酸麻黄碱含量的高效液相色谱法.方法 采用C18色谱柱(250 mm×4.6 mm,5μm),以乙腈-含0.1%三乙胺的0.1%磷酸溶液(3:97)为流动相,流速为1.0 mL/min,检测波长为205 nm,柱温为30℃.结果 盐酸麻黄碱质量浓度在0.01~0.32 g/L范围内与峰面积呈良好线性关系,精密度RSD为0.13%,平均加样回收率为99.95%,RSD为2.22%(n=9).结论 该方法简便、快捷、重现性好,可作为小儿解表止咳口服液的质量控制方法.  相似文献   
115.
目的 观察康复新液联合银花抗病毒口服液治疗疱疹性口炎的疗效观察,寻找治疗疱疹性口炎的有效方法.方法 选取2011年1月1日-2012年12月30日于湖南省儿童医院口腔科就诊符合条件的患儿90例,随机分为治疗组和对照组各45例,均根据情况给予常规退热,补液,止痛等对症治疗.治疗组以康复新液局部喷口腔,银花抗病毒口服液口服,对照组以开喉剑喷雾剂局部喷口腔,蒲地兰口服液口服,两组疗程均为7d,观察疗效.结果 治疗7d后,治疗组总有效率95.6%,高于对照组有效率71.1%,未见严重不良反应,两组比较差异有统计学意义(P<0.05).结论 康复新液联合银花抗病毒口服液治疗疱疹性口炎,安全有效,值得临床推广应用.  相似文献   
116.
为观察滋阴润肠流膏口服治疗功能性便秘的临床效果,将60例功能性便秘患者随机分为治疗组和对照组,每组各30例。治疗组采用口服滋阴润肠流膏治疗,对照组采用口服六味能消胶囊治疗。两组均以4周为1个疗程,观察两组的临床疗效,并对治愈患者随访2个月,观察远期疗效。结果显示,治疗组在排便不尽感、排便困难、排便频率及大便性状等方面疗效明显优于对照组(P〈0.05)。结果表明,滋阴润肠流膏口服治疗功能性便秘更为有效、安全,具有服用剂量较小、便于久服、服用适口、生物利用度高、强健补益等独特的优点。  相似文献   
117.
朱克清 《中国校医》2014,(7):538-540
目的建立白酒中的环己基氨基磺酸钠快速灵敏的分析方法。方法以ACQUITY UPLC BEH C_(18)柱(2.1mm×50mm,1.7μm)为分离柱,甲醇和乙酸胺为流动相梯度淋洗,用串联质谱测定,采用电喷雾电离负离子模式进行多反应监测。结果该方法的标准曲线线性良好,相关系数r=0.999,检出限(3S/N)为0.1μg,测定下限(10S/N)为0.03μg。测定值的相对标准偏差〈5.2%(n=6)。有较好的准确度和精密度,回收率92%~106%。应用该方法对35批白酒中的环己基氨基磺酸钠进行测定,阳性率11.4%。结论该方法操作简单快速,分离良好,适宜白酒中环己基氨基磺酸钠的快速测定。  相似文献   
118.
目的:比较4种方法处理静脉输液液面过低的效果,为临床选择适合的处理方法提供参考.方法:选择静脉输液时因未及时发现液体输完而造成液面低于莫菲氏滴管的患者800例次,根据液面下降程度随机分成4组,每组200例次,即每组选下降10cm、20cm、30cm、40cm各50例次,分别采用轻弹气泡法、缠绕滴管法、分段折叠输液管法、顺行排气法处理液面过低.结果:液面低于莫菲氏滴管末端约10cm时,适宜选用轻弹气泡法、缠绕滴管法、分段折叠输液管法;液面低于莫菲氏滴管末端约20cm时,适宜选用缠绕滴管法、分段折叠输液管法;液面低于莫菲氏滴管末端约30cm时,适宜选用分段折叠输液管法.结论:轻度液面过低可用轻弹气泡法、缠绕滴管法、分段折叠输液管法解决,中度液面过低可用缠绕滴管法和分段折叠输液管法解决,重度液面过低适合选用分段折叠输液管法解决.  相似文献   
119.
A rapid, selective and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method has been developed and validated for the determination of pitavastatin in human plasma. Following a liquid–liquid extraction, both the analytes and internal standard telmisartan were separated on a Luna C18 column with a mobile phase consisted of acetonitrile–methanol–1% formic acid in water (50:25:25, v/v/v). Mass spectrometric detection involved electrospray ionization in the positive ion mode followed by multiple reaction monitoring (MRM) of the transitions at m/z 421.9 → 290.1 for pitavastatin and m/z 515.2 → 276.2 for the IS. The assay for pitavastatin showed good linearity (r ≥ 0.99) over the ranges 0.2–400 ng/ml, with a lower limit of quantitation of 0.2 ng/ml. Accuracy and precision for the assay were determined by calculating the intra- and inter-batch variation of quality control (QC) samples at three concentration levels, with relative standard deviations (RSD) of less than 15% for both analytes. The mean extraction recovery of pitavastatin and IS were both above 70%. Matrix effect hasn't been found in this method. The method has been successfully applied to a clinic pharmacokinetic study of pitavastatin administered.  相似文献   
120.
IntroductionmicroRNAs (miRNAs) are frequently dysregulated in many human cancers including colorectal cancer (CRC) and are useful candidate biomarkers in liquid biopsy of cancer for their stability in the blood.MethodsWe compared the expression of microRNA-9 (miR-9) in tissues (n = 357) and sera (n = 109) of CRC patients to determine whether miR-9 in serum reflects that in the cancer tissue in parallel. Also, we examined the miR-9 role in CRC by in vitro functional studies in four CRC cell lines.ResultsOn multivariate analysis of colorectal cancer tissues and sera, miR-9 low expressions were significantly associated pN stage (tissues; p < 0.01, serum; p = 0.013), and clinical stage (tissues; p < 0.01, serum; p = 0.031). Moreover, patients with low miR-9 expression had shorter survival than those with high miR-9 expression (log-rank test, tissue; p = 0.021, serum; p = 0.011). miR-9 level in serum reflects that in the tumor. The CRC cells with low miR-9 expression was significantly increased cell proliferation, migration, invasion and colony formation than cells with high miR-9 expression.ConclusionSerum miR-9 is an useful early detection marker in liquid biopsy of CRC and overexpression of miR-9 in CRC may be a novel prognostic marker as well.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号